Skip to main content
Top
Published in: AIDS and Behavior 11/2015

01-11-2015 | Original Paper

Behavioral Economics Matters for HIV Research: The Impact of Behavioral Biases on Adherence to Antiretrovirals (ARVs)

Authors: Sebastian Linnemayr, Chad Stecher

Published in: AIDS and Behavior | Issue 11/2015

Login to get access

Abstract

Behavioral economics (BE) has been used to study a number of health behaviors such as smoking and drug use, but there is little knowledge of how these insights relate to HIV prevention and care. We present novel evidence on the prevalence of the common behavioral decision-making errors of present-bias, overoptimism, and information salience among 155 Ugandan HIV patients, and analyze their association with subsequent medication adherence. 36 % of study participants are classified as present-biased, 21 % as overoptimistic, and 34 % as having salient HIV information. Patients displaying present-bias were 13 % points (p = 0.006) less likely to have adherence rates above 90 %, overoptimistic clients were 9 % points (p = 0.04) less likely, and those not having salient HIV information were 17 % points (p < 0.001) less likely. These findings indicate that BE may be used to screen for future adherence problems and to better design and target interventions addressing these behavioral biases and the associated suboptimal adherence.
Literature
1.
go back to reference Charness G, Gneezy U. Incentives to exercise. Econometrica. 2009;77(3):909–31.CrossRef Charness G, Gneezy U. Incentives to exercise. Econometrica. 2009;77(3):909–31.CrossRef
2.
go back to reference Heil S, Higgins S, Bernstein I, et al. Effects of voucher-based incentives on abstinence from cigarette smoking and fetal growth among pregnant women. Addiction. 2008;103:1009–18.PubMedCentralCrossRefPubMed Heil S, Higgins S, Bernstein I, et al. Effects of voucher-based incentives on abstinence from cigarette smoking and fetal growth among pregnant women. Addiction. 2008;103:1009–18.PubMedCentralCrossRefPubMed
3.
go back to reference Barsky R, Juster T, Kimball M, Shapiro M. Preference parameters and behavioral heterogeneity: an experimental approach in the health and retirement study. Q J Econ. 1997;112(2):537–79.CrossRef Barsky R, Juster T, Kimball M, Shapiro M. Preference parameters and behavioral heterogeneity: an experimental approach in the health and retirement study. Q J Econ. 1997;112(2):537–79.CrossRef
4.
go back to reference Tversky A, Kahneman D. Judgment under uncertainty: heuristics and biases. Science. 1974;185(4157):1124–31.CrossRefPubMed Tversky A, Kahneman D. Judgment under uncertainty: heuristics and biases. Science. 1974;185(4157):1124–31.CrossRefPubMed
5.
go back to reference Kahneman D, Tversky A. Prospect theory: an analysis of decisions under risk. Econometrica. 1979;47(2):263–91.CrossRef Kahneman D, Tversky A. Prospect theory: an analysis of decisions under risk. Econometrica. 1979;47(2):263–91.CrossRef
6.
go back to reference Frederick S, Loewenstein G, O’Donoghue T. Time discounting and time preference: a critical review. J Econ Lit. 2002;14:351–401.CrossRef Frederick S, Loewenstein G, O’Donoghue T. Time discounting and time preference: a critical review. J Econ Lit. 2002;14:351–401.CrossRef
7.
go back to reference Thaler R, Sunstein C. Libertarian paternalism. Am Econ Rev. 2003;93(2):175–9.CrossRef Thaler R, Sunstein C. Libertarian paternalism. Am Econ Rev. 2003;93(2):175–9.CrossRef
8.
go back to reference Loewenstein G, Brennan T, Volpp K. Asymmetric paternalism to improve health behaviors. JAMA. 2007;298(20):2415–7.CrossRefPubMed Loewenstein G, Brennan T, Volpp K. Asymmetric paternalism to improve health behaviors. JAMA. 2007;298(20):2415–7.CrossRefPubMed
9.
go back to reference Rice T. The behavioral economics of health and health care. Annu Rev Publ Health. 2013;34:431–7.CrossRef Rice T. The behavioral economics of health and health care. Annu Rev Publ Health. 2013;34:431–7.CrossRef
10.
go back to reference Gebhardt W, Maes S. Integrating social-psychological frameworks for health behavior research. Am J Health Behav. 2001;25:528–36.CrossRefPubMed Gebhardt W, Maes S. Integrating social-psychological frameworks for health behavior research. Am J Health Behav. 2001;25:528–36.CrossRefPubMed
11.
go back to reference Janz N, Becker M. The health belief model: a decade later. Health Educ Behav. 1984;11(1):1–47.CrossRef Janz N, Becker M. The health belief model: a decade later. Health Educ Behav. 1984;11(1):1–47.CrossRef
12.
go back to reference Armitage C, Conner M. Social cognition models and health behavior: a structured review. Psychol Health. 2000;15:173–89.CrossRef Armitage C, Conner M. Social cognition models and health behavior: a structured review. Psychol Health. 2000;15:173–89.CrossRef
13.
go back to reference Ariely D. Predictably irrational. New York: Harper Collins; 2008. Ariely D. Predictably irrational. New York: Harper Collins; 2008.
14.
go back to reference Préau M, Apostolidis T, Francois C, Raffi F, Spire B. Time perspective and quality of life among HIV-infected patients in the context of HAART. AIDS Care. 2007;19(4):449–58.CrossRefPubMed Préau M, Apostolidis T, Francois C, Raffi F, Spire B. Time perspective and quality of life among HIV-infected patients in the context of HAART. AIDS Care. 2007;19(4):449–58.CrossRefPubMed
15.
go back to reference McHorney C. The adherence estimator: a brief, proximal screener for patient propensity to adhere to prescription medications for chronic disease. Curr Med Res Opin. 2009;25(1):215–38.CrossRefPubMed McHorney C. The adherence estimator: a brief, proximal screener for patient propensity to adhere to prescription medications for chronic disease. Curr Med Res Opin. 2009;25(1):215–38.CrossRefPubMed
16.
go back to reference O’Donoghue T, Rabin M. Doing it now or later. Am Econ Rev. 1999;89(1):103–24.CrossRef O’Donoghue T, Rabin M. Doing it now or later. Am Econ Rev. 1999;89(1):103–24.CrossRef
17.
go back to reference Benartzi S. Save more tomorrow. New York: Pengiun; 2012. Benartzi S. Save more tomorrow. New York: Pengiun; 2012.
18.
go back to reference Kahneman D. Thinking, fast and slow. New York: Macmillan; 2011. Kahneman D. Thinking, fast and slow. New York: Macmillan; 2011.
20.
go back to reference Palm R, Hodgson M. After a California Earthquake: attitude and behavior change. The University of Chicago Geography Research Paper No. 233; 1992. Palm R, Hodgson M. After a California Earthquake: attitude and behavior change. The University of Chicago Geography Research Paper No. 233; 1992.
21.
go back to reference Coller M, Williams M. Eliciting individual discount rates. Exp Econ. 1999;2:107–27.CrossRef Coller M, Williams M. Eliciting individual discount rates. Exp Econ. 1999;2:107–27.CrossRef
22.
go back to reference Cameron L, Shah M. Risk-taking behavior in the wake of natural disasters. J Hum Resour. 2015;50(12):484–515. Cameron L, Shah M. Risk-taking behavior in the wake of natural disasters. J Hum Resour. 2015;50(12):484–515.
23.
go back to reference Arnsten J, Demas P, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis. 2001;33:1417–23.PubMedCentralCrossRefPubMed Arnsten J, Demas P, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis. 2001;33:1417–23.PubMedCentralCrossRefPubMed
24.
go back to reference Bangsberg D, Ware N, Simoni J. Adherence without access to antiretroviral therapy in sub-Saharan Africa? AIDS. 2006;20:140–1.CrossRefPubMed Bangsberg D, Ware N, Simoni J. Adherence without access to antiretroviral therapy in sub-Saharan Africa? AIDS. 2006;20:140–1.CrossRefPubMed
25.
go back to reference Turner B. Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients. J Infect Dis. 2002;185:S143–51.CrossRefPubMed Turner B. Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients. J Infect Dis. 2002;185:S143–51.CrossRefPubMed
26.
go back to reference Raffa J, Tossonian H, Grebely J, Petkau J, DeVlaming S, Conway B. Intermediate highly active antiretroviral therapy adherence thresholds and empirical models for the development of drug resistance mutations. J AIDS. 2008;47(3):397–9. Raffa J, Tossonian H, Grebely J, Petkau J, DeVlaming S, Conway B. Intermediate highly active antiretroviral therapy adherence thresholds and empirical models for the development of drug resistance mutations. J AIDS. 2008;47(3):397–9.
27.
go back to reference Scanlon M, Vreeman R. Current strategies for improving access and adherence to antiretroviral therapies in resource-limited settings. HIV/AIDS–Res Palliat Care. 2013;5:1–17. Scanlon M, Vreeman R. Current strategies for improving access and adherence to antiretroviral therapies in resource-limited settings. HIV/AIDS–Res Palliat Care. 2013;5:1–17.
28.
go back to reference Fogarty L, Roter D, Larson S, Burke J, Gillespie J, Levy R. Patient adherence to HIV medication regimens: a review of published and abstract reports. Patient Educ Couns. 2002;46(2):93–108.CrossRefPubMed Fogarty L, Roter D, Larson S, Burke J, Gillespie J, Levy R. Patient adherence to HIV medication regimens: a review of published and abstract reports. Patient Educ Couns. 2002;46(2):93–108.CrossRefPubMed
Metadata
Title
Behavioral Economics Matters for HIV Research: The Impact of Behavioral Biases on Adherence to Antiretrovirals (ARVs)
Authors
Sebastian Linnemayr
Chad Stecher
Publication date
01-11-2015
Publisher
Springer US
Published in
AIDS and Behavior / Issue 11/2015
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-015-1076-0

Other articles of this Issue 11/2015

AIDS and Behavior 11/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine